Technetium (99mTc) exametazime: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
Line 23: Line 23:
[[Category:Nuclear medicine]]
[[Category:Nuclear medicine]]
[[Category:Medical imaging]]
[[Category:Medical imaging]]
<gallery caption="Technetium_(99mTc)_exametazime">
File:Tc-99m_exametazime_skeletal.svg|Skeletal structure of Technetium-99m exametazime
File:Exametazime.png|Technetium-99m exametazime
</gallery>

Latest revision as of 01:26, 18 February 2025

Technetium (99mTc) exametazime[edit]

Technetium (99mTc) exametazime is a radiopharmaceutical used in nuclear medicine imaging. It is commonly known by its brand name Ceretec. This article provides an overview of its uses, mechanism of action, and potential side effects.

Uses[edit]

Technetium (99mTc) exametazime is primarily used for brain imaging, specifically in the diagnosis of cerebral blood flow and brain perfusion. It is commonly employed in the evaluation of patients with suspected cerebrovascular diseases, such as stroke or dementia.

Mechanism of Action[edit]

The radiopharmaceutical works by binding to the hexamethylpropyleneamine oxime (HMPAO) ligand, which is then labeled with the radioactive isotope technetium-99m (99mTc). Once injected into the patient's bloodstream, the compound rapidly crosses the blood-brain barrier and accumulates in brain tissue. The emitted gamma radiation from the technetium-99m is detected by a gamma camera, allowing for the visualization and assessment of cerebral blood flow.

Side Effects[edit]

Technetium (99mTc) exametazime is generally well-tolerated, with minimal side effects reported. However, some individuals may experience mild allergic reactions, such as rash or itching, at the injection site. Rarely, more severe allergic reactions can occur, including anaphylaxis. Patients should be monitored closely during and after the administration of the radiopharmaceutical.

References[edit]

<references />